Treatment of fibrous dysplasia: focus on denosumab

References

• Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol. 2008;22(1):55–69.
   PubMed Web of Science ®Google Scholar
• Marie PJ, de Pollak C, Chanson P, et al. Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol. 1997;150(3):1059–1069.
   PubMed Web of Science ®Google Scholar
• Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–1695.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ozono K, Kasayama S, et al. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest. 1996;98(1):30–35.
   PubMed Web of Science ®Google Scholar
• Allard L, Demoncheaux N, Machuca-Gayet I, et al. Biphasic Effects of Vitamin D and FGF23 on Human Osteoclast Biology. Calcif Tissue Int. 2015;97(1):69–79.
   PubMed Web of Science ®Google Scholar
• Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis. 2019;14(1):139.
   PubMed Web of Science ®Google Scholar
• Infante M, Fabi A, Cognetti F, et al. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38(1):12.
   PubMed Web of Science ®Google Scholar
• Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011;6(4):e19234.
   PubMed Web of Science ®Google Scholar
• Casimiro S, Vilhais G, Gomes I, et al. The roadmap of RANKL/RANK pathway in cancer. Cells. 2021;10(8):1978.
   PubMed Web of Science ®Google Scholar
• Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221–1230.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170(2):427–435.
   PubMed Web of Science ®Google Scholar
• Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15(6):457–475.
   PubMed Web of Science ®Google Scholar
• Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–1234.
   PubMed Web of Science ®Google Scholar
• Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–323.
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl). 2001;79(5–6):243–253.
   PubMed Web of Science ®Google Scholar
• Cervellati C, Romani A, Cremonini E, et al. Higher urinary levels of 8-Hydroxy-2ʹ-deoxyguanosine are associated with a worse RANKL/OPG ratio in postmenopausal women with osteopenia. Oxid Med Cell Longev. 2016;2016:6038798.
   PubMed Web of Science ®Google Scholar
• El-Gazzar A, Högler W. Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis. Int J Mol Sci. 2021;22(2):625.
   Web of Science ®Google Scholar
• Saggio I, Remoli C, Spica E, et al. Constitutive expression of Gsα(R201C) in mice produces a heritable, direct replica of human fibrous dysplasia bone pathology and demonstrates its natural history. J Bone Miner Res. 2014;29(11):2357–2368.
   PubMed Web of Science ®Google Scholar
• Remoli C, Michienzi S, Sacchetti B, et al. Osteoblast-specific expression of the fibrous dysplasia (FD)-causing mutation Gsα(R201C) produces a high bone mass phenotype but does not reproduce FD in the mouse. J Bone Miner Res. 2015;30(6):1030–1043.
   PubMed Web of Science ®Google Scholar
• Raimondo D, Remoli C, Astrologo L, et al. Changes in gene expression in human skeletal stem cells transduced with constitutively active Gsα correlates with hallmark histopathological changes seen in fibrous dysplastic bone. PLoS One. 2020;15(1):e0227279.
   PubMed Web of Science ®Google Scholar
• Zhao X, Deng P, Iglesias-Bartolome R, et al. Expression of an active Gα(s) mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance. Proc Natl Acad Sci U S A. 2018;115(3):E428–E437.
   PubMed Web of Science ®Google Scholar
• Palmisano B, Spica E, Remoli C, et al. RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease. J Bone Miner Res. 2019;34(12):2171–2182.
   PubMed Web of Science ®Google Scholar
• Hsiao EC, Boudignon BM, Halloran BP, et al. Gs G protein-coupled receptor signaling in osteoblasts elicits age-dependent effects on bone formation. J Bone Miner Res. 2010;25(3):584–593.
   PubMed Web of Science ®Google Scholar
• Khan SK, Yadav PS, Elliott G, et al. Induced Gnas(R201H) expression from the endogenous Gnas locus causes fibrous dysplasia by up-regulating Wnt/β-catenin signaling. Proc Natl Acad Sci U S A. 2018;115(3):E418–E427.
   PubMed Web of Science ®Google Scholar
• Lung H, Hsiao EC, Wentworth KL. Advances in models of fibrous Dysplasia/McCune-Albright syndrome. Front Endocrinol (Lausanne). 2020;10(925). DOI:https://doi.org/10.3389/fendo.2019.00925
   Google Scholar
• de Castro LF, Burke AB, Wang HD, et al. Activation of RANK/RANKL/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden. J Bone Miner Res. 2019;34(2):290–294.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Denosumab: an investigational drug for the management of postmenopausal osteoporosis. Biologics. 2008;2(4):645–653.
   PubMedGoogle Scholar
• Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059–1066.
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Stouch B, Schroeder J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011;49(2):162–173.
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483–4492.
   PubMed Web of Science ®Google Scholar
• Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24(2):182–195.
   PubMed Web of Science ®Google Scholar
• Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27(7):1462–1470.
   PubMed Web of Science ®Google Scholar
• Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. Osteoporos Int. 2014;25(2):777–782.
   PubMed Web of Science ®Google Scholar
• Benhamou J, Gensburger D, Chapurlat R. Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment. Joint Bone Spine. 2014;81(6):549–550.
   PubMed Web of Science ®Google Scholar
• Eller-Vainicher C, Rossi DS, Guglielmi G, et al. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. Clin Cases Miner Bone Metab. 2016;13(3):253–256.
   PubMedGoogle Scholar
• Raborn LN, Burke AB, Ebb DH, et al. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporos Int. 2021;32(9):1889–1893.
   PubMed Web of Science ®Google Scholar
• Meier ME, van der Bruggen W, van de Sande MAJ, et al. Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases. Bone Rep. 2021;14:101058.
   PubMedGoogle Scholar
• Majoor BCJ, Papapoulos SE, Dijkstra PDS, et al. Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates. J Clin Endocrinol Metab. 2019;104(12):6069–6078.
   PubMed Web of Science ®Google Scholar
• van der Bruggen W, Vriens D, Meier ME, et al. Denosumab reduces lesional fluoride skeletal burden on Na[18F]F PET-CT in patients with fibrous dysplasia/McCune–Albright syndrome. J Clin Endocrinol Metab. 2021;106(8):e2980–e2994.
   PubMed Web of Science ®Google Scholar
• Meier ME, Clerkx SN, Winter EM, et al. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res. 2021;36(9):1729–1738.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Riminucci M, Kuznetsov SA, Cherman N, et al. Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone. 2003;33(3):434–442.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Johnson A, Hablani N, et al. Tocilizumab in the treatment of a polyostotic variant of fibrous dysplasia of bone. Rheumatology. 2015;54(9):1747–1749.
   PubMed Web of Science ®Google Scholar
• Trials C. TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE (TOCIDYS). (Ed.^(Eds); 2019.
   Google Scholar
• Insogna KL, Briot K, Imel EA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-Linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383–1393.
   PubMed Web of Science ®Google Scholar
• Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13–R30.
   PubMed Web of Science ®Google Scholar
• Gladding A, Szymczuk V, Auble BA, et al. Burosumab treatment for fibrous dysplasia. Bone. 2021;150:116004.
   PubMed Web of Science ®Google Scholar
• Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res. 2006;21(Suppl 2):114–119.
   Google Scholar
• Weidner LD, Wakabayashi Y, Stolz LA, et al. PET imaging of phosphodiesterase-4 identifies affected dysplastic bone in McCune-Albright syndrome, a genetic mosaic disorder. J Nucl Med. 2020;61(11):1672–1677.
   PubMed Web of Science ®Google Scholar
• Guille JT, Kumar SJ, MacEwen GD. Fibrous dysplasia of the proximal part of the femur. Long-term results of curettage and bone-grafting and mechanical realignment. J Bone Joint Surg Am. 1998;80(5):648–658.
   PubMed Web of Science ®Google Scholar
• Leet AI, Boyce AM, Ibrahim KA, et al. Bone-grafting in polyostotic fibrous dysplasia. J Bone Joint Surg Am. 2016;98(3):211–219.
   PubMed Web of Science ®Google Scholar
• Mbundi L, Meikle ST, Busquets R, et al. Gadolinium tagged osteoprotegerin-mimicking peptide: a novel magnetic resonance imaging biospecific contrast agent for the inhibition of osteoclastogenesis and osteoclast activity. Nanomaterials (Basel). 2018;8(6):399.
   Google Scholar